Treatment Strategies for Myoclonic Seizures and Epilepsy Syndromes with Myoclonic Seizures

Epilepsia

Volumn 44, Issue SUPPL. 11, 2003, Pages 27-37

  Wheless, James W ^a   Sankar, Raman ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Antiepileptic drug therapy; Epilepsy; Myoclonic seizures

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BICUCULLINE; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

COMORBIDITY; CONFERENCE PAPER; EPILEPSY; HUMAN; KETOGENIC DIET; MEDICAL DECISION MAKING; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; VAGUS NERVE STIMULATION;

EID: 0242659215     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.44.s11.5.x     Document Type: Conference Paper

References (167)

1. Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("epilim"). Dev Med Child Neurol 1977;19:9-25.
2. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29:147-54.
3. Dulac O. Epileptic encephalopathy. Epilepsia 2001;42(suppl 3):23-6.
4. Hallett M. Myoclonus and myoclonic syndromes. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:2717-23.
5. Janz D, Inoue Y, Seino M. Myoclonic seizures. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:591-603.
6. ILAE Commission report. Myoclonus and epilepsy in childhood. Epilepsia 1997;38:1251-4.
7. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001;23:277-83.
8. White HS, Woodhead JH, Franklin MR, et al. Experimental selection, quantification, and evaluation of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:99-122.
9. Ferrendelli JA, Holland KD, McKeon AC, Covey DF. Comparison of the anticonvulsant activities of ethosuximide, valproate, and a new anticonvulsant, thiobutyrolactone. Epilepsia 1989;30:617-22.
10. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 1999;40:1471-83.
11. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27-34.
12. Taylor CP. Gabapentin: mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:829-41.
13. Holmes GL, Pearl PL. Gabapentin. In: Pellock JM, Dodson WE, Bourgeois BFD, eds. Pediatric epilepsy: diagnosis and therapy. 2nd ed. New York: Demos Medical Publishing, 2001:453-9.
14. Sankar R, Derdiarian AT. Vigabatrin. CNS Drug Rev 1998;4:260-74.
15. Kanthasamy AG, Vu TQ, Yun RJ, Truong DD. Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus. Eur J Pharmacol 1996;297:219-24.
16. Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: 1. Anticonvulsant profile in mice and rats. Epilepsia 1986;27:483-9.
17. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51.
18. Guerrini R, Dravet C, Genton C, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
19. Guerrini R, Belmonte A, Parmeggiani L, Perucca E. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999;21:420-4.
20. Janszky J, Rasonyi G, Halasz P, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases. Clin Neuropharmacol 2000;23:86-9.
21. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
22. Killiam KF, Killiam EK, Naquet R. Mise en evidence chez certains singes d'un syndrome myoclonique [in French]. C R Acad Sci (Paris) 1966;262:1010-2.
23. Meldrum B, Wilkins AJ. Photosensitive epilepsy in man and the baboon: integration of pharmacological and psychosocial evidence. In: Schwartzkroin PA, Wheal HV, eds. Electrophysiology of epilepsy. London: Academic Press, 1984:51-77.
24. McLean MJ. Gabapentin. In: Wiley E, ed. The treatment of epilepsy: principles and practice, 2nd ed. Baltimore: Williams & Wilkins, 1997:884-898.
25. Meldrum BS, Horton R. Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, gamma-acetylenic GABA (4-amino-hex-5-ynoic acid) and gamma-vinyl GABA (4-amino-hex-5-enoic acid). Psychopharmacology 1978;59:47-50.
26. Gundlach AL. Disorder of the inhibitory glycine receptor: inherited myoclonus in Poll Hereford calves. FASEB J 1990;4:2761-6.
27. Avanzini G, Fariello R. Animal models of epilepsies. In: Avanzini G, Regesta G, Tanganelli P, Avoli M, eds. Molecular and cellular targets for anti-epileptic drugs. London: John Libbey Eurotext, 1997:91-109.
28. A-receptor transmission in transgenic mice. J Neurosci 2002;22:2505-12.
29. AAN Practice Guidelines. American Academy of Neurology Web site. Available at: http//www.aan.com/professionals/practice/index.cfm. (Accessed January 6, 2003.)
30. Ohtahara S, Yamatogi Y. Severe encephalopathic epilepsy in early infancy. In: Pellock J, Dodson WE, Bourgeois BFD, eds. Pediatric epilepsy: diagnosis and therapy. 2nd ed. New York: Demos, 2001:193-9.
31. Trevathan E. Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol 2002;17(suppl 2):2S9-22.
32. Mackay M, Weiss S, Snead OC III. Treatment of infantile spasms: an evidence-based approach. Int Rev Neurobiol 2002;49:157-84.
33. Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991;6(suppl):2S30-7.
34. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia 1989;30:430-7.
35. Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-21.
36. Curatolo P, Seri S, Verdecchia M, Bombardieri R. Infantile spasms in tuberous sclerosis complex. Brain Dev 2001;23:502-7.
37. Curatolo P, Verdecchia M, Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev 2001;23:649-53.
38. Hancock E, Osborne JP, Milner P. The treatment of West syndrome: a Cochrane review of the literature to December 2000. Brain Dev 2001;23:624-34.
39. Mikati MA, Lepejian GA, Holmes GL. Medical treatment of patients with infantile spasms. Clin Neuropharmacol 2002;25:61-70.
40. Dreifuss F, Farwell J, Holmes G, et al. Infantile spasms. Comparative trial of nitrazepam and corticotropin. Arch Neurol 1986;43:1107-10.
41. 6 treatment in West syndrome. Brain Dev 2001;23:654-57.
42. Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002;26:181-5.
43. Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. Dev Med Child Neurol 2001;43:416-20.
44. Nabbout R. A risk-benefit assessment of treatments for infantile spasms. Drug Saf 2001;24:813-28.
45. Suzuki Y, Imai K, Toribe Y, et al. Long-term response to zonisamide in patients with West syndrome. Neurology 2002;58:1556-9.
46. Kossoff EH, Pyzik PL, McGrogan JR, Vining EP, Freeman JM. Efficacy of the ketogenic diet for infantile spasms. Pediatrics 2002;109:780-3.
47. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000;356:1638-42.
48. Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999;40:1618-26.
49. Todt H, Muller D. The therapy of benign myoclonic epilepsy in infants. Epilepsy Res Suppl 1992;6:137-9.
50. Clancy RR. Valproate: an update-the challenge of modern pediatric seizure management. Curr Prob Pediatr 1990;20:161-233.
51. Wheless JW, Constantinou JE. Lennox-Gastaut syndrome. Pediatr Neurol 1997;17:203-11.
52. Jeavons PM, Clark JE. Sodium valproate in treatment of epilepsy. Br Med J 1974;2:584-6.
53. Covanis A, Gupta AK, Jeavons PM. Sodium valproate monotherapy and polytherapy. Epilepsia 1982;23:693-720.
54. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982;65:504-23.
55. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
56. Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as addon therapy to valproic acid in Lennox-Gastaut syndrome. Epilepsy Res 1999;34:91-7.
57. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group [published correction appears in N Engl J Med. 1998;339:851-2]. N Engl J Med 1997;337:1807-12.
58. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group [published correction appears in N Engl J Med. 1998;339:851-2]. N Engl J Med 1997;337:1807-12.
59. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Epilepsia 1997;38:68-73.
60. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000;41(suppl 1):S86-90.
61. Glauser TA. Topiramate in the catastrophic epilepsies of childhood. J Child Neurol 2000;15:S14-21.
62. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(suppl 1):S7-13.
63. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-7.
64. Coppola G, Caliendo G, Veggiotti P, et al. Topiramate as addon drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res 2002;51:147-53.
65. Vining EP. Clinical efficacy of the ketogenic diet. Epilepsy Res 1999;37:181-90.
66. Wheless JW, Baumgartner J, Ghanbari C. Vagus nerve stimulation and the ketogenic diet. Neurol Clin 2001;19:371-407.
67. Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson RO. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999;103:778-82.
68. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001;42:1148-52.
69. Wheless JW. Vagus nerve stimulation. In: Wyllie E, ed. The treatment of epilepsy: principles and practice. 3rd ed. Baltimore: Lippincott, Williams and Wilkins, 2001:1007-15.
70. Majoie HJ, Berfelo MW, Aldenkamp AP, Evers SM, Kessels AG, Renier WO. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol 2001;18:419-28.
71. Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol 2001;16:843-8.
72. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996;46:852-3.
73. Lortie A, Chiron C, Mumford J, Dulac O. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993;43(suppl 5):S24-7.
74. Bonanni P, Parmeggiani L, Guerrini R. Different neurophysiologic patterns of myoclonus characterize Lennox-Gastaut syndrome and myoclonic astatic epilepsy. Epilepsia 2002;43:609-15.
75. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic Disord 2002;4:217-25.
76. Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002;33:122-32.
77. Dulac O, Kaminska A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 1997;12(suppl 1):S23-8.
78. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
79. Buoni S, Grosso S, Fois A. Lamotriginein typical absence epilepsy. Brain Dev 1999;21:303-6.
80. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39:1329-33.
81. Wolf P. Juvenile myoclonic epilepsy. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey Eurotext, 1992:313-27.
82. Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol 2002;17(suppl 2):2S34-42.
83. Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002;11:406-10.
84. Tassinari CA, Bureau M, Thomas P. Epilepsy with myoclonic absences. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds. Epileptic syndromes in infancy, childhood, and adolescence. London: John Libbey Eurotext, 1992:151-60.
85. Richens A. Treatment of eyelid myoclonia with absences. In: Duncan JS, Panayiotopoulos CP, eds. Eyelid myoclonia with absences. London: John Libbey Eurotext, 1996:117-20.
86. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:285-94.
87. Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long-term response to therapy. Epilepsia 1989;30(suppl 4):S19-23.
88. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28(suppl 2):S8-11.
89. Grunewald RA, Panayiotopoulos CP. Juvenile myoclonic epilepsy. A review. Arch Neurol 1993;50:594-8.
90. Biton V, Montouris GD, Ritter F, et al. A randomized placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7.
91. Resor SR Jr, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990;40:1677-81.
92. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.
93. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1757-8.
94. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56:1424-5.
95. Guerrini R, Bonanni P, Patrignani A, et al. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures. A newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. Brain 2001;124:2459-75.
96. Plaster NM, Uyama E, Uchino M, et al. Genetic localization of the familial adult myoclonic epilepsy (FAME) gene to chromosome 8q24. Neurology 1999;53:1180-3.
97. Mikami M, Yasuda T, Terao A, et al. Localization of a gene for benign adult familial myoclonic epilepsy to chromosome 8q23.3-q24.1. Am J Hum Genet 1999;65:745-51.
98. Labauge P, Amer LO, Simonetta-Moreau M, et al. Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). Neurology 2002;58:941-4.
99. Conry JA. Progressive myoclonic epilepsies. J Child Neurol 2002;17(suppl 1):S80-4.
100. Wheless JW, Kim HL. Adolescent seizures and epilepsy syndromes. Epilepsia 2002;43(suppl 3):33-52.
101. Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001;46:283-7.
102. Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38:928-31.
103. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;29:109-14.
104. Hirano M, DiMauro S. Primary mitochondrial disease. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:2563-70.
105. Aberg L, Kirveskari E, Santavuori P. Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia 1999;40:796-9.
106. Aberg L, Heiskala H, Vanhanen SL, et al. Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis. (INCL). Neuropediatrics 1997;28:77-9.
107. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000;2:209-12.
108. Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostino D, Andermann F. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58:781-6.
109. Genton P, Guerrini R. Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology 1990;40:1412-6.
110. Hurd RW, Wilder BJ, Helveston WR, Uthman BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996;47:1264-8.
111. Edwards MJ, Hargreaves IP, Heales SJ, et al. N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects. Neurology 2002;59:1447-9.
112. Smith B, Shatz R, Elisevich K, Bespalova IN, Burmeister M. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 2000;41:1046-8.
113. Berkovic SF, Cochius J, Andermann E, Andermann F. Progressive myoclonus epilepsies: clinical and genetic aspects. Epilepsia 1993;34(suppl 3):S19-30.
114. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 1997;120:479-90.
115. Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol 1999;45:75-81.
116. Pueschel SM, Louis S, McKnight P. Seizure disorders in Down syndrome. Arch Neurol 1991;48:318-20.
117. Stafstrom CE, Patxot OF, Gilmore HE, Wisniewski KE. Seizures in children with Down syndrome: etiology, characteristics and outcome. Dev Med Child Neurol 1991;33:191-200.
118. Silva ML, Cieuta C, Guerrin R, Plouin P, Livet MO, Dulac O. Early clinical and EEG features of infantile spasms in Down syndrome. Epilepsia 1996;37:977-82.
119. Goldberg-Stern H, Strawsburg RH, Patterson B, et al. Seizure frequency and characteristics in children with Down syndrome. Brain Dev 2001;23:375-8.
120. Moller JC, Hamer HM, Oertel WH, Rosenow F. Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS). Seizure 2002;11(suppl A):303-5.
121. Battaglia A, Carey JC, Wright TJ. Wolf-Hirschhorn (4p-) syndrome. Adv Pediatr 2001;48:75-113.
122. Guerrini R, Gobbi G, Genton P, et al. Chromosomal abnormalities. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:2533-46.
123. Franz DN, Glauser TA, Todor C, Williams S. Topiramate therapy of epilepsy associated with Angelman's syndrome. Neurology 2000;54:1185-8.
124. Boles RG, Seashore MR, Mitchell WG, Kollros PR, Mofidi S, Novotny EJ. Glucose transporter type 1 deficiency: a study of two cases with video-EEG. Eur J Pediatr 1999;158:978-83.
125. De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325:703-9.
126. Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;56:411-2.
127. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-4.
128. Schauer R, Singer M, Saltuari L, Kofler M. Suppression of cortical myoclonus by levetiracetam. Mov Disord 2002;17:411-5.
129. Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood epilepsy. JAMA 1980;244:785-8.
130. Sotaniemi K. Valproic acid in the treatment of nonepileptic myoclonus. Arch Neurol 1982;39:448-9.
131. Sheth RD, Gidal BE. Intravenous valproic acid for myoclonic status epilepticus. Neurology 2000;54:1201.
132. Gericke CA, Picard F, Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Epileptic Disord 1999;1:159-65.
133. Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-7.
134. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
135. Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994;344:1375-6.
136. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-6.
137. Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000;9:590-4.
138. Uldall P, Buchholt JM. Clinical experiences with topiramate in children with intractable epilepsy. Eur J Paediatr Neurol 1999;3:105-11.
139. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies-our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:79-85.
140. Leppik IE. Zonisamide. Epilepsia 1999;40(suppl 5):S23-9.
141. Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999;21:157-61.
142. Kishi T, Nejihashi Y, Kajiyama M, Ueda K. Successful zonisamide treatment for infants with hypsarrhythmia. Pediatr Neurol 2000;23:274-7.
143. Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38:1035-8.
144. Sakamoto K, Kurokawa T, Tomita S, et al. Effects of zonisamide in children with epilepsy. Curr Therapeutic Res 1988;13:378-83.
145. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002;17:87-96.
146. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000;2:99-105.
147. Uthman BM, Reichl A. Progressive myoclonic epilepsies. Curr Treat Options Neurol 2002;4:3-17.
148. Obeso JA, Artieda J, Quinn N, et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11:529-36.
149. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63-8.
150. Genton P, Guerrini R, Remy P. Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry 1999;32(suppl 1):49-53.
151. Kastelijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25:225-30.
152. Smith K, Betts T, Greenhill L. Levetiracetam: a promising option for the treatment of juvenile myoclonic epilepsy. Presented at: 4th European Congress on Epileptology; October 11, 2000; Firenze.
153. Murphy JV, Wheless JW, Schmoll CM. Left vagal nerve stimulation in six patients with hypothalamic hamartomas. Pediatr Neurol 2000;23:167-8.
154. Maggio V, Wheless J. Dietary treatment of seizures from a hypothalamic hamartoma. In: Schmidt D, Schachter SC, eds. 110 Puzzling cases of epilepsy. London: Martin Dunitz, 2001:434-8.
155. Regis J, Bartolomei F, de Toffol B, et al. Gamma knife surgery for epilepsy related to hypothalamic hamartomas. Neurosurgery 2000;47:1343-51.
156. Kramer U, Spector S, Nasser W, Siomin V, Fried I, Constantini S. Surgical treatment of hypothalamic hamartoma and refractory seizures: a case report and review of the literature. Pediatr Neurosurg 2001;34:40-2.
157. Palmini A, Chandler C, Andermann F, et al. Resection of the lesion in patients with hypothalamic hamartomas and catastrophic epilepsy. Neurology 2002;58:1338-47.
158. Labar D. Vagus nerve stimulation for intractable epilepsy in children. Dev Med Child Neurol 2000;42:496-9.
159. Labar D, Nikolov B, Tarver B, Fraser R. Vagus nerve stimulation for symptomatic generalized epilepsy: a pilot study. Epilepsia 1998;39:201-5.
160. Wheless JW, Maggio V. Vagus nerve stimulation therapy in patients younger than 18 years. Neurology 2002;59(suppl 4):S21-5.
161. Katyal NG, Koehler AN, McGhee B, Foley CM, Crumrine PK. The ketogenic diet in refractory epilepsy: the experience of Children's Hospital of Pittsburgh. Clin Pediatr (Phila) 2000;39:153-9.
162. Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 1998;102:1358-63.
163. Nordli DR Jr, Kuroda MM, Carroll J, et al. Experience with the ketogenic diet in infants. Pediatrics 2001;108:129-33.
164. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001;42:790-2.
165. Scheyer RD, Assaf BA, Spencer SS, Mattson RH. Gabapentin related myoclonus [Abstract]. Epilepsia 1996;37(suppl 5):203.
166. Viani F, Romeo A, Viri M, et al. Seizure and EEG patterns in Angelman's syndrome. J Child Neurol 1995;10:467-71.
167. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41:479-81.